

# Progress of the NSCLC Revolution

Questioning the Experts CME

**TUESDAY, SEPTEMBER 25, 2018**

**TIME:** 7:00 AM | **REGISTRATION AND BREAKFAST:** 6:30 AM

**VENUE:** METRO TORONTO CONVENTION CENTER (MTCC) NORTH BUILDING, 255 FRONT STREET WEST,  
TORONTO, ONTARIO M5V 2W6, CANADA

**ROOM:** 107

Medscape

**LIVE!**

Please visit:

[www.medscape.org/symposium/nsclc-revolution-registration](http://www.medscape.org/symposium/nsclc-revolution-registration)

## MODERATOR



**Tony S.K. Mok, BMSc, MD, FASCO, FRCP(C),  
FRCP (Edin), FHKCP, FHKAM (Med)**

Professor and Chairman  
Department of Clinical Oncology  
The Chinese University of Hong Kong  
Hong Kong, China

## FACULTY



**Fabrice Barlesi, MD, PhD**

Professor of Medicine  
Aix-Marseille University  
Marseille, France



**Edward B. Garon, MD**

Associate Professor of Medicine  
David Geffen School of Medicine  
University of California, Los Angeles, United States



**Sanjay Popat, PhD, FRCP**

Consultant Medical Oncologist  
Royal Marsden Hospital  
London, United Kingdom

## AGENDA

6:30 AM

**Breakfast and Registration**

7:00 AM

**Welcome and Introductions**

Tony S.K. Mok, BMSc, MD, FASCO,  
FRCP(C), FRCP (Edin), FHKCP,  
FHKAM (Med)

7:05 AM

**Molecular Testing in NSCLC:**

**Where Are We Going?**

Fabrice Barlesi, MD, PhD

7:20 AM

**Treating New Molecular  
Targets in NSCLC: How Are  
We Progressing?**

Sanjay Popat, PhD, FRCP

7:35 AM

**Immunotherapy in NSCLC:  
Where Have We Got to?**

Edward B. Garon, MD

7:45 AM

**How Are We Doing in  
the Delivery of the  
NSCLC Revolution?**

Panel

## TARGET AUDIENCE

This activity is intended for oncologists, pulmonologists, and pathologists.

## LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the:

- Current and evolving best diagnostic practice
- The supporting clinical data for the available and emergent immunotherapies and clinical implications
- Emerging molecular targets, potential treatments, and implications

Demonstrate greater confidence in their ability to:

- Understand and apply evidence-based selection of the right treatment approach for the individual patient across the continuum of care

## ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### For Physicians

Medscape, LLC designates this live activity for a maximum of 1.0 **AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## DISCLAIMER

*This program was approved by the IASLC 19th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 19th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.*

Medscape



JOINTLY ACCREDITED PROVIDER<sup>™</sup>  
INTERPROFESSIONAL CONTINUING EDUCATION

Please visit:

[www.medscape.org/symposium/nsclc-revolution-registration](http://www.medscape.org/symposium/nsclc-revolution-registration)

Medscape  
Oncology

